A Real-world Clinical Study of Kapok Initiative
NCT04735991 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2021-02-03
Summary
This study is a prospective and effective research study. The aim is to assess the difference in the quality of life of the family members of patients with colorectal cancer after application of follow-up disease management using mobile network terminals and routine clinical treatment follow-up management. The hypothesis is that the application of mobile-based disease management system significantly improves the quality of life of the patients' family members, thereby improving the quality of life of the patients' families.
Approximately 100 families of colorectal cancer patients who had been diagnosed as high-risk stage II or stage III and required adjuvant chemotherapy XELOX regimen within 6 months after initial diagnosis were randomly assigned to the control and study groups at a 1: 1 ratio, with approximately 50 cases in the control group and about 50 patients in the study group. The reason for choosing these tumors is because the patients with these tumors will present a series of clinical symptoms during the treatment, which requires family members to take care of them. All patient and their family demographics, questionnaires on quality of life of patient's family, adverse events and other information will be collected.
The study uses a network-centric randomization system. In the randomization process, stratified randomization will be carried out according to the education level of the patient's family members (junior college degree or above vs. below college degree). The family members of the patients participating in the study will be randomly assigned to the tumor patient management platform or clinical routine treatment follow-up group.
Family members of all patients will be followed up to 2 months after randomization, or withdrew from the study (with the preceding events as the end point). Unless the patient's family member withdraws from the study, lost to follow-up, or the study is terminated, the patient is considered to be in the study. Family members of patients who are randomly assigned to the full management platform need to participate in a 60 minutes concentrated training session for 27 days, taught by experts online. The content of the lectures includes medical treatment guidelines, pain relief, family rehabilitation, family communication, family roles, early screening prevention, Medical insurance and other aspects. The contents of the online courses are: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level ; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation.
Conditions
- Quality of Life
Interventions
- BEHAVIORAL
-
Kapok Initiative
The detailed process is: 1. After randomization, the Kapok assistant will contact the patient's family 2. The family of the patient joins the "Kapok Initiative". They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation.
Sponsors & Collaborators
-
QTC care
collaborator UNKNOWN -
Chinese Academy of Medical Sciences
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-08
- Primary Completion
- 2021-09-30
- Completion
- 2022-10-31
Countries
- China
Study Locations
More Related Trials
-
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429 ·Status: ACTIVE_NOT_RECRUITING
-
Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients
NCT02321813 ·Status: COMPLETED ·Phase: NA
-
Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
NCT02777437 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
NCT01268943 ·Status: COMPLETED ·Phase: PHASE1
-
Maintenance Treatment With Capecitabine in Colorectal Cancer Patients
NCT02027363 ·Status: UNKNOWN ·Phase: PHASE2
-
Multicenter, Prospective, RCT:Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
NCT03042000 ·Status: UNKNOWN ·Phase: NA
-
Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
NCT06637215 ·Status: RECRUITING ·Phase: NA
-
Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer
NCT01080547 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
NCT00075556 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
NCT06557668 ·Status: RECRUITING
-
MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer
NCT03400657 ·Status: UNKNOWN
-
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
NCT06417476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
NCT06958419 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy
NCT00414232 ·Status: COMPLETED
-
Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer
NCT01577511 ·Status: COMPLETED
-
Colorectal Adenoma Canceration in FAP
NCT04531930 ·Status: NOT_YET_RECRUITING
-
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
NCT05720559 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy
NCT00918827 ·Status: COMPLETED
-
Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer
NCT02316535 ·Status: UNKNOWN ·Phase: PHASE3
-
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
NCT04215731 ·Status: RECRUITING ·Phase: PHASE3
-
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
NCT02860234 ·Status: COMPLETED
-
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
NCT05575635 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.
NCT03787667 ·Status: UNKNOWN
-
Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker
NCT02043821 ·Status: UNKNOWN ·Phase: NA
-
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
NCT00960427 ·Status: WITHDRAWN ·Phase: PHASE1